Evolent Health, Inc. (EVH) · Nov 5, 2026 · Earnings
In line — Adjusted EPS $0.06 vs ~$0.06 consensus; revenue $725.4M vs ~$727.1M
Evolent’s third-quarter earnings were broadly in line, while renewed contracts and a higher 2026 EBITDA guide offset worsening medical-cost pressure.
Evolent is in the middle of a specialty-care growth push, especially oncology and surgical management, while building an AI-enabled platform intended to support higher-margin expansion. The prior quarter had already lifted 2026 revenue guidance to $2.6-$2.7 billion and set a $120-$135 million Adjusted EBITDA range, so the broad growth story was established before this filing.
The quarter was essentially in line, not a clean beat. Revenue of $725.4 million was just below the published consensus near $727.1 million, while adjusted EPS of $0.06 matched expectations. Revenue growth was substantial, but the quality of that growth was less convincing: Adjusted EBITDA fell to $34.3 million from $39.0 million and margin compressed to 4.7% from 8.1%. The filing’s 93.0% medical expense ratio, up from 85.0%, shows the main operational drag is claims cost rather than weak demand.
| Metric | Q3 2026 | Q3 2025 | Consensus / prior guide |
|---|---|---|---|
| Revenue (Financial Results) | $725.4M | $479.5M (+51.3%) | ~$727.1M |
| Adjusted EBITDA (Adjusted EBITDA reconciliation) | $34.3M (-12.1%) | $39.0M | — |
| Adjusted EBITDA margin (Adjusted EBITDA reconciliation) | 4.7% | 8.1% | — |
| Adjusted EPS (Adjusted income reconciliation) | $0.06 | $0.05 | ~$0.06 |
| Medical expense ratio (Revenue by solution) | 93.0% | 85.0% | — |
| 2026 revenue guidance (Business Outlook) | $2.6B-$2.7B | — | $2.6B-$2.7B prior |
| 2026 Adjusted EBITDA guidance (Business Outlook) | $130M-$135M | — | $120M-$135M prior |
The more important news is the higher full-year profit floor. Evolent reiterated its revenue range but raised the bottom of its Adjusted EBITDA range from $120 million to $130 million, effectively signaling confidence that current execution and future launches can offset near-term medical-cost pressure. The filing states, “Incorporating its year-to-date performance, the Company is reiterating its 2026 revenue guidance range to $2.6billion to $2.7billion and raising its Adjusted EBITDA range to $130.0million to $135.0million.”
Contract momentum supports the growth thesis, but the payoff is forward-looking. Evolent renewed its largest Surgical Management customer for four years and expanded an oncology relationship across additional states covering approximately 1 million commercial lives, with a January 1, 2027 launch. Those are meaningful validation points for retention and cross-selling, but they do not materially affect the reported quarter and must still convert into revenue and margin improvement. The filing says, “First, we renewed our largest Surgical Management customer contract for an additional four years.” 〔0〕 It also says, “Second, we are expanding our relationship with an existing client to provide oncology services across several additional states, representing approximately 1 million Commercial lives, with a January 1, 2027 go-live.” 〔1〕
The unresolved issue is whether scale can overcome worsening medical economics. Revenue is growing rapidly, but the 8-point increase in the medical expense ratio and the year-over-year decline in Adjusted EBITDA show that the current mix is not yet producing the margin expansion investors were expecting from the platform transition. The raised EBITDA guide keeps the story on track, but this quarter did not prove that the margin problem is solved.
Bottom line: Evolent delivered an in-line quarter and raised its profit guidance, with new oncology and renewal wins strengthening the forward story. The result is modestly constructive, but the sharp medical-cost and margin deterioration keeps it from being a clean positive surprise.
Oncology expansion go-live across roughly 1 million lives, January 1, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!